Screener
GeneDx Holdings WGS Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Revenue | ||
| Diagnostic test revenue | $101,299 | $85,759 |
| Other revenue | 955 | 1,356 |
| Total revenue | 102,254 | 87,115 |
| Cost of services | 34,043 | 28,639 |
| Gross profit | 68,211 | 58,476 |
| Research and development | 19,804 | 12,577 |
| Selling, general and administrative | 74,591 | 50,450 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's total revenue?
- GeneDx Holdings (WGS) reported total revenue of $102.25M in Q1 2026.
- How has GeneDx Holdings's total revenue changed year-over-year?
- GeneDx Holdings's total revenue increased by 17.4% year-over-year, from $87.12M to $102.25M.
- What is the long-term trend for GeneDx Holdings's total revenue?
- Over 4 years (2021 to 2025), GeneDx Holdings's total revenue has grown at a 19.1% compound annual growth rate (CAGR), from $212.2M to $427.54M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about GeneDx Holdings's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude